These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19811443)

  • 1. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
    Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
    Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Gentile V
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase and diseases of the central nervous system.
    Hoffner G; Djian P
    Front Biosci; 2005 Sep; 10():3078-92. PubMed ID: 15970562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
    Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
    Burguera EF; Love BJ
    Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifaceted role of transglutaminase in neurodegeneration: review article.
    Karpuj M; Steinman L
    Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
    Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
    J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
    Titta F; Iannaccone M; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of brain substrates of transglutaminase by functional proteomics supports its role in neurodegenerative diseases.
    André W; Nondier I; Valensi M; Guillonneau F; Federici C; Hoffner G; Djian P
    Neurobiol Dis; 2017 May; 101():40-58. PubMed ID: 28132929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminases - possible drug targets in human diseases.
    Gentile V; Cooper AJ
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
    Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
    Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
    Zainelli GM; Ross CA; Troncoso JC; Muma NA
    J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
    Siegel M; Khosla C
    Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.